参考文献
[1] 陈万青,郑荣寿,曾红梅,等.2011年中国恶性肿瘤发病和死亡分析[J].中国肿瘤,2015,24(1): 1-10.
[2] HANAHAN D, WEINBERG RA. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5):646-674.
[3] WU WK, CHO CH, LEE CW, et al. Dysregulation of cellular signaling in gastric cancer[J]. Cancer Lett, 2010, 295(2): 144-153.
[4] ABDEL-RAHMAN O. Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: preclinical and clinical aspects[J]. Crit Rev Oncol Hematol, 2015, 3(1): 18-27.
[5] CLARKE JM, HURWITZ HI, RANGWALA F. Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective[J]. Cancer Treat Rev, 2014, 40(9): 1065-1072.
[6] KAWALEC P, LOPUCH S, MIKRUT A. Effectiveness of Targeted Therapy in Patients With Previously Untreated Metastatic Breast Cancer: A Systematic Review and Meta-Analysis[J]. Clin Breast Cancer, 2014. http://dx.doi.org/10.1016/j.clbc.2014.10.006.
[7] OHTSU A, SHAH MA, VAN CUTSEM E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study[J]. J Clin Oncol, 2011, 29(30): 3968-3976.
[8] SHEN L, LI J, XU J, et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)[J]. Gastric Cancer, 2015, 18(1): 168-176.
[9] JAVLE M, SMYTH EC, CHAU I. Ramucirumab: successfully targeting angiogenesis in gastric cancer[J]. Clin Cancer Res,2014, 20(23): 5875-5881.
[10] FUCHS CS, TOMASEK J, YONG CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial[J]. Lancet, 2014, 383(9911): 31-39.
[11] WILKE H, MURO K, VAN CUTSEM E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial[J]. Lancet Oncol, 2014, 15(11): 1224-1235.
[12] LI J, QIN S, XU J, et al. A randomized, double-blind, multicenter, phase, three-arm, placebo-control study of apatinib as third-line treatment in patients with metastatic gastric carcinoma [J]. J Clin Oncol, 2011, 29(Suppl): 4019.
[13] SUN W, POWELL M, O'DWYER PJ, et al. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203[J]. J Clin Oncol, 2010, 28: 2947-2951.
[14] BANG YJ, KANG YK, KANG WK, et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer[J]. Invest New Drugs, 2011, 29: 1449-1458.
[15] MOEHLER M, MUELLER A, HARTMANN JT, et al. An openlabel, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer[J]. Eur J Cancer, 2011, 47: 1511-1520.
[16] G?MEZ-MART?N C1, SALAZAR R, MONTAGUT C, GIL-MART?N M, et al. A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer[J]. Invest New Drugs,2013, 31(2): 390-398.
[17] LEE KW, PARK SR, OH DY, et al. Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer[J]. Invest New Drugs, 2013, 31(6): 1547-1558.
[18] YANG W, RAUFI A, KLEMPNER SJ. Targeted therapy for gastric cancer: molecular pathways and ongoing investigations[J]. Biochim Biophys Acta, 2014, 1846(1): 232-237.
[19] KIM ST, JANG HL, LEE SJ, et al. Pazopanib, a novel multitargeted kinase inhibitor, shows potent in vitro antitumor activity in gastric cancer cell lines with FGFR2 amplification[J]. Mol Cancer Ther, 2014, 13(11): 2527-2536.
[20] SINGH R, KIM WJ, KIM PH, et al. Combined blockade of HER2 and VEGF exerts greater growth inhibition of HER2-overexpressing gastric cancer xenografts than individual blockade[J]. Exp Mol Med, 2013, 45:e52.
[21] 杜春霞,陈闪闪,刘潇衍,等.重组人血管内皮抑素联合多西他赛?铂类和氟尿嘧啶类一线治疗进展期胃癌的临床观察[J]. 临床肿瘤学杂志, 2014, (10): 925-928.
[22] PARK DO J, THOMAS NJ, YOON C, et al.Vascular endothelial growth factor a inhibition in gastric cancer[J]. Gastric Cancer, 2015, 18(1): 33-42.
[23] ILSON DH. Angiogenesis in gastric cancer: hitting the target?[J]. Lancet, 2014, 383(9911): 4-6.
[24] Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma[J]. Natur, 2014, 513(7517): 202-209.
[25] DVORAK HF. Tumors: wounds that do not heal-redux[J]. Cancer Immunol Res, 2015, 3(1): 1-11.
① 本网版权均属于现代医院杂志社,转载、摘编应在授权范围内使用,应注明"来源出处:《现代医院》杂志社"。违者本网将追究相关法律责任。
② 如有疑问和问题请联系现代医院杂志社服务热线:020-83310901 83310902
2020年,每个人心中都可能萦绕着一个问题 疫情之后,是爆发报复性反弹?还是缓慢有......
广东省医院各学科恢复不平衡,但总体向好 。 疫情在国内虽然被控制了,但不少医院......